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Abstract: Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an
extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying
activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell
proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) in the HCC4006rErlo0.5 NSCLC
cell line adapted to erlotinib as a model of acquired drug resistance. Constitutive CIP2A resulted in a
constitutive activation of Akt signaling. The proteasome inhibitor bortezomib was able to reduce
CIP2A levels, which resulted in an activation of protein phosphatase 2A and deactivation of Akt.
Combination experiments with erlotinib and bortezomib revealed a lack of interaction between the
two drugs. However, the effect size of bortezomib was higher in HCC4006rErlo0.5, compared to the
erlotinib-sensitive HCC4006 cells, as indicated by an increase in Emax (0.911 (95%CI 0.867–0.954)
vs. 0.585 (95%CI 0.568–0.622), respectively) and decrease in EC50 (52.4 µM (95%CI 46.1–58.8 µM) vs.
73.0 µM (95%CI 60.4–111 µM), respectively) in the concentration–effect model, an earlier onset of cell
death induction, and a reduced colony surviving fraction (0.38 ± 0.18 vs. 0.95 ± 0.25, respectively,
n = 3, p < 0.05). Therefore, modulation of CIP2A with bortezomib could be an interesting approach to
overcome drug resistance to erlotinib treatment in NSCLC.
Keywords: non-small cell lung cancer; epidermal growth factor receptor; drug resistance; cell
proliferation regulating inhibitor of protein phosphatase 2A; bortezomib
1. Introduction
Non-small cell lung cancers (NSCLCs) harboring activating mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain are typically treated with EGFR
tyrosine kinase inhibitors [1]. However, the vast majority of these tumors develop drug
resistance within several months. A broad spectrum of resistance mechanisms has been
identified that includes the acquisition of secondary mutations in the EGFR; activation of
bypassing signals by the amplification of EGFR-related family members, such as the human
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epidermal growth factor (HER)-2 or the unrelated c-Met; phenotypic transformation; or
the activation of downstream signaling molecules [2–4].
While next generation sequencing has enabled deep insights into the genetic alter-
ations of tumor cells, nongenetic alterations driven by posttranslational modification or
changes in protein stability may also be relevant for tumor progression and drug resistance
yet are far less accessible than genetic alterations. Signaling of the EGFR receptor can be
imagined as a bow-tied system of network signaling, consisting of a broad ligand input
module, including the EGFR-related members of the HER family; an output module that
consists of multiple signaling pathways; and a core process that, by biochemical interactions
of adaptor proteins with the receptor, tightly regulates the signaling network [5]. In order
to identify changes within this interactome of adaptor proteins at the EGFR receptor, we
have developed a method based on affinity purification of the receptor and high-resolution
mass spectrometry [6]. We applied this technique to NSCLC cells adapted to grow in the
presence of EGFR tyrosine kinase inhibitors as a cellular model of acquired drug resistance
and found a constitutive activation of Akt in a subline of the NSCLC cell line HCC4006
adapted to the EGFR tyrosine kinase inhibitor erlotinib (HCC4006rErlo0.5) [7].
Here, we investigated the molecular mechanism that caused constitutive Akt activa-
tion and strategies to revert drug resistance. While cell proliferation regulating inhibitor
of phosphatase 2A (CIP2A) was downregulated upon EGFR inhibition by erlotinib in
parental HCC4006 cells, it was constitutively present in HCC4006rErlo0.5 cells. Pharmaco-
logical repression of CIP2A in HCC4006rErlo0.5 cells by bortezomib reactivated protein
phosphatase 2A, which resulted in dephosphorylation and inactivation of Akt signaling.
Furthermore, p21 and p27 were induced, and cells were arrested in cell cycle phase G2/M.
Quantitative pharmacodynamics interaction modeling revealed antagonistic interactions
between erlotinib and bortezomib at concentrations higher than 100 nM in HCC4006 cells
and a higher potency of bortezomib in HCC4006rErlo0.5 cells without any combinatory
effect, suggesting a switch in oncogene addiction.
2. Materials and Methods
2.1. Chemicals
All chemicals were of analytical grade. Ribonuclease A, propidium iodide, and
phosphate buffered saline (PBS) were purchased from Sigma–Aldrich Chemie GmbH
(Munich, Germany). Inhibitors erlotinib and MK2206 were supplied by Selleckchem
(Munich, Germany), and bortezomib was supplied by Cell Signaling Technology (New
England Biolabs GmbH, Frankfurt/Main, Germany).
Primary antibodies against pEGFR (Phospho-EGF Receptor (Tyr1068) (D7A5) XP®®
Rabbit mAb), EGFR (EGF Receptor (D38B1) XP®® Rabbit mAb), pAkt (Phospho-Akt
(Ser473) (D9E) XP®® Rabbit mAb), Akt (Akt Rabbit pAb), pMAPK (Phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb), MAPK (p44/42 MAPK (Erk1/2)
(3A7) Mouse mAb), pSTAT3 (Phospho-Stat3 (Tyr705) (D3A7) XP®® Rabbit mAb), STAT3
(Stat3 (79D7) Rabbit mAb), p53 (1C12 Mouse mAb), as well as antimouse (horse radish
peroxixdase (HRP)-linked goat IgG) and antirabbit (HRP-linked goat IgG) secondary
antibodies were obtained from Cell Signaling Technology (New England Biolabs GmbH,
Frankfurt/Main, Germany). Antibodies for CIP2A (2G10-3B5, mouse monoclonal IgG2b),
p-PP2A (p-PP2A-Cα/β Rabbit pAb (Tyr 307)), and dem-PP2A (demethylated PP2A-C
(4B7), Mouse mAb) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, Texas,
USA). p27 (Anti-p27 KIP 1 Rabbit mAb [Y236]), phospho-p27 (Recombinant Anti-p27
KIP 1 (phospho S10) antibody (EP233(2)Y)), and p21 (Anti-p21 Rabbit mAb (EPR3993))
antibodies were obtained from abcam (Cambridge, MA, USA). Anti-Glycerinaldehyd-3-
Phosphat-Dehydrogenase (GAPDH) Mouse mAb (H86504M) was obtained from Meridian
Life Science,®® Inc., (Memphis, TN, USA).
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2.2. Cell Culture
The NSCLC cell line HCC4006 (HCC) was purchased from ATCC (Manassas, VA,
USA). The subline HCC4006rERLO0.5, with acquired resistance to erlotinib, was established
as previously described [8] and derived from the Resistant Cancer Cell Line (RCCL) collec-
tion (https://research.kent.ac.uk/industrial-biotechnology-centre/the-resistant-cancer-
cell-line-rccl-collection/; last access 19 March 2021) [9]. All cell lines were cultured in
DMEM/HAM’s F12 medium (Sigma–Aldrich Chemie GmbH, Munich, Germany) supple-
mented with 10% fetal bovine serum (Gibco by Thermo Fisher Scientific, BV & Co KG,
Braunschweig, Germany) at 37 ◦C in a humidified 5% CO2. Medium of HCC4006rERLO0.5
cells was additionally supplemented with 0.5 µM erlotinib.
2.3. Western Immunoblotting
HCC4006 and their subline HCC4006rERLO0.5, adapted to grow in the presence of
0.5 µM erlotinib, were incubated with inhibitors MK2206 (Akt) and bortezomib (CIP2A),
and resulting effects on downstream signaling proteins were assessed by SDS-PAGE and
Western Blotting. Cells were plated in 6-well plates at 2 × 105 cells/well for HCC4006 and
5 × 105 cells/well for HCC4006rERLO0.5. After overnight adhesion, cells were incubated
as indicated, washed with ice cold PBS, and each sample lysed with 100 µl lysis buffer
(50 mM Tris pH 7.6, 100 mM NaCl, 5 mM EDTA, 0.2 mM sodium vanadate, 0.1 % Triton®®
X-100). We separated 50 µg of total protein on 10% SDS-polyacrylamide gels, and protein
was transferred to nitrocellulose membranes through electroblotting (6 mA/cm2) for 1.5 h.
Membranes were incubated with 10% milk powder in TBST buffer (Tris 2.42 g/L, NaCl
8.5 g/L, Tween-20 0.05%) as blocking reagent (2 h or overnight at 4 ◦C). Primary antibodies
were incubated overnight at 4 ◦C and used in a dilution of 1:1000, except anti-EGFR-
antibody, which was used in a 1:3000 dilution. Secondary HRP-conjugated antibodies were
incubated in a dilution of 1:3000 for 1 h at room temperature. Chemiluminescence signals
were developed with Immunstar Western CTM (BioRad, Munich, Germany), and specific
bands were visualized by ChemoCam imaging system (Intas, Göttingen, Germany).
2.4. Cell Proliferation Analysis
Cells were seeded into 96-well plates (40,000 cells/well for HCC4006 and
80,000 cells/well for HCC4006rERLO0.5) and incubated with inhibitors solubilized in a max-
imum of 0.5 µM DMSO for 72 h. Cell viability was assessed by measuring transformation
of the formazan derivative 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT) by mitochondrial NADPH at 37 ◦C for 4 h at 570 nm (SpectraMax Plus 384 Mi-
croplate Reader, Molecular Devices, Sunnyvale, CA, USA) and normalized to the DMSO
solvent control after background subtraction.
2.5. Cell Cycle Analysis
For cell cycle analysis, cells were trypsinized and 0.5 × 106 cells per sample fixed and
permeabilized in 1 mL ice-cold ethanol (70%) at least 1 h at 4 ◦C. After fixation, the cells
were centrifuged for 5 min at 150× g, washed with PBS, and incubated with 25 µL RNase
A (1 mg/mL; Life Technologies, Carlsbad, CA, USA) in 500 µL PBS for 30 min at 37 ◦C.
Following further centrifugation and washing steps, cells were carefully resuspended in
500 µL FACS buffer (MACSQuant Running Buffer, Miltenyi Biotec, Bergisch Gladbach,
Germany) and stained with 25 µL propidium iodide (1 mg/mL in PBS, Sigma–Aldrich,
Steinheim, Germany) with gentle vortexing. Samples of 5000 cells were analyzed using
flow cytometry (MacsQuant, Miltenyi Biotec, Bergisch Gladbach, Germany).
2.6. Genetic Mutation Analysis
Genomic DNA was isolated using the MagNA Pure 24 total NA isolation kit (Roche
Molecular Systems, Inc.), as described by the manufacturer’s protocol. DNA library of
genes of interest were prepared using the TruSight Tumor 15 kit (Illumina, Inc., San Diego,
CA, USA) and sequenced using a MiniSeq Rapid High output Reagent Kit on a MiniSeq
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System (Illumina, Inc.). Sequence analysis was performed using Illumina BaseSpace
Variant Interpreter with the BaseSpace Annotation engine 1.6.2.0 based on the human hg19
reference genome (Illumina, Inc.).
2.7. Data Analysis
Combination Index according to Chou–Talalay
In order to quantify combination effects, the combination index theory of Ting-Chao
Chou and Paul Talalay was used [10], which is based on the concentration additivity
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describe doses or concentrations of the drugs to result in a specific effect x when applied as







where Dm describes the median effect dose, fa the affected fraction, fu the unaffected
fraction, and m the shape of the dose effect curve.
The combination index was calculated using the software CompuSyn (ComboSyn Inc.
Paramus, NJ, USA).
2.8. GPDI-Model Structure
The General PharmacoDynamic Interaction (GDPI) Model [12] was used for quanti-
tative description of the interactions of combined inhibitor exposure. Briefly, this model
combines the mechanistic description of sigmoid Emax-type models with the additive
components of Loewe Additivity (LA) or Bliss Independence (BI) models. An interaction
parameter is implemented on either the maximal effect, Emax, or the concentration of
0.5 × Emax, EC50, (or, in rare cases, on both), allowing quantitative interpretation of the
interaction. This interaction parameter is dependent on the perpetrator concentration,
allowing for a dynamic rather than a static interaction. Equation (2) shows an example
using BI, based GPDI implemented on maximum effect:





















In cases of sparse or less informative data, several simplifications of the model struc-
ture are possible. Firstly, a joint interaction parameter can be estimated (IntAB = IntBA),
assuming the nature of the interaction to affect both drugs similarly. Secondly, the in-
teraction EC50 can be assumed equal to the monotherapy EC50 (EC50Int,AB = EC50B and
EC50Int,BA = EC50A), assuming the nature of the interaction to be similar to the nature of
the drug effect. Lastly, the structural model can be simplified from a sigmoidal model to a
linear or constant effect model in some cases.
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2.9. Model Estimation and Evaluation Tools
Several model evaluation tools were used in this work to choose the best model and
assess its quality. Parameter estimation was performed by maximation of the log likelihood,
which was approached using minimization of the extended least squares error (ELS) with
a combined error model [13] (Equation (3)):












SIG2PROP = prop error ∗ PRED2i SIG2ADD = add errorσ2 = (SIG2ADD + SIG2PROP)
2
with PREDi as the ith prediction, OBSi the ith experimental observation, and n the number
of experimental observations. This error was minimized using a sequential application of a
robust Nelder–Mead algorithm, followed by a conjugate gradient method for refinement.
Models were evaluated by the precision of their parameter estimates, calculated from
the inverse of the square root of the diagonal elements of the Fisher Information matrix,
calculated from the Hessian. To perform model selection, models with sufficient parameter
precision were compared based on the Akaike Information Criterion (AIC), which favors
parsimony by including a penalty term for the number of parameters (k):
AIC = min(ELS) + 2 ∗ k (4)
Finally, selected models were compared to the experimental data for deviations, where
more than 15% deviation from observed effect or no overlap with the 95% confidence
interval of the t-distribution estimated form the experimental observations were considered
significant deviations. The entire model selection and evaluation workflow was established
using R (v. 3.4.4) and RStudio (v. 1.1.447).
2.10. Live Cell Imaging
Cells were cultured in 35 mm µ-cell culture plates (Ibidi, Planegg, Germany) in
DMEM/F12-Ham medium by plating 300,000 cells per well and controlled for confluency
of 60–70%. Prior to the experiment, cells were washed with PBS, and medium was replaced
with fresh medium containing 10 nM bortezomib. The plates were then immediately
placed under the time lapse-microscope (Biostation II, Nikon Instruments, Düsseldorf,
Germany). During the experiment, the incubation chamber was kept at 37 ◦C and 5% CO2
atmosphere. Images were taken every 3 min for 72 h and converted into time lapse movies
of 90 s duration.
2.11. Colony Formation Assay
We treated 1 × 105 cells with either 10 nM bortezomib or DMSO as control for 24 h.
Cells were then washed with PBS, trypsinized to produce a single-cell suspension, and
counted. Then, 5 × 103 cells were plated on a 150 × 20 mm petri dish and grown for
2 weeks. The medium was replaced every 3 days. After 2 weeks, the cells were fixed and
stained with a 1% formaldehyde 0.05% (m/v) crystal violet solution for 20 min at room
temperature. After extensive washing with deionized water, the plates were imaged and
the colonies counted manually. One colony was defined as >50 cells. The surviving fraction
(SF) was calculated as
SF = (no. of colonies formed after treatment)/(no. of cells seeded × PE) (5)
with the plating efficiency (PE, %) calculated from
PE = (no. of colonies formed)/(no. of cells seeded) × 100
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2.12. Statistical Analysis
All experiments were carried out in triplicates. Data were analyzed for statistical
differences using student’s t-test for single comparisons and one-way ANOVA analyses for
multiple comparisons on one dataset. Tests were performed using the GraphPad Prism
Version 5.02 software (GraphPad Software, Inc., San Diego, CA, USA).
3. Results
3.1. The CIP2A/PP2A/Akt Signaling Module Is Constitutively Active in HCC4006rErlo0.5 Cells
We initially screened fifteen common tumor genes for secondary mutations, which
may cause constitutive Akt activation, using next generation sequencing. The investigated
tumor genes were AKT1, BRAF, EGFR, ERBB2, FOXL2, GNA11, GNAQ, KIT, KRAS,
MET, NRAS, PDGFRA, PIK3CA, RET, and TP53. While the original mutations present
in the HCC4006 cells (EGFR d746-750, TP53 Y205H) were also found in the adapted
HCC4006rErlo0.5 cell line, no secondary mutation was found in the investigated tumor
oncogenes (Figure 1).
Figure 1. Genetic characteristics of native HCC4006 and HCC4006rErlo0.5 cells adapted to grow in the presence of 0.5 µM
erlotinib. DNA was isolated, and a DNA library of fifteen common tumor genes was prepared using the TrusightTumor15
panel and analyzed on a MiniSeq System using Illumina BaseSpace Variant Interpreter and BaseSpace Annotation Engine
1.6.2.0 (Illumina, Inc., San Diego, CA, USA). Black bullets denote the identified genetic variant of the respective gene.
To further characterize the constitutive activation of Akt, the cells were stimulated
with epidermal growth factor (EGF) and the EGFR signaling activity, represented by the
STAT-, Akt, and MAPK pathways, was followed over time. In HCC4006 cells, EGF-induced
EGFR signaling peaked at 5 min after stimulation and returned to the basal level after
60 min. A similar signaling kinetic was observed in HCC4006rErlo0.5 cells for all observed
EGFR signaling pathways, except for the Akt signaling. In HCC4006rErlo0.5 cells, Akt
signaling was constitutively activated and not affected by upstream receptor signaling
(Figure 2A).
Cell proliferation regulating inhibitor of phosphatase 2A (CIP2A) has been shown
to activate Akt signaling via inhibition of Akt dephosphorylation in different types of
cancer, including lung cancer [14–18]. Therefore, we investigated protein levels of CIP2A
in response to stimulation or inhibition of EGFR activity in HCC4006 and HCC4006rErlo0.5
cells. In HCC4006 cells, EGF stimulation did not affect CIP2A levels, but EGFR inhibition
by erlotinib markedly reduced the cellular CIP2A amount. Reduced CIP2A levels resulted
in protein phosphatase 2A (PP2A) activation, as indicated by reduced phosphorylation of a
tyrosine in position 307 of the amino acid sequence and demethylation of a lysine in position
309, followed by an almost complete loss of Akt phosphorylation. In HCC4006rErlo0.5
cells, neither EGF nor erlotinib affected CIP2A protein levels or PP2A activity (Figure 2B,
Supplementary Figure S1).
Similar effects were observed when downstream substrates of Akt were investigated.
In HCC4006 cells, EGFR inhibition resulted in a slight decrease of p53 and a robust increase
of the cell cycle regulator p27. In HCC4006rErlo0.5 cells, these proteins were completely
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unaffected (Figure 2C). Finally, we observed a feedback regulation in both of the cell lines
in that inhibition of Akt activity resulted in a reduction of CIP2A protein and a reduction
of the PP2A inactivity marker pY307 (Figure 2D).
Figure 2. Akt signaling is constitutively active in HCC4006rErlo0.5 cells adapted to grow in the presence of 0.5 µM erlotinib.
Cells were (A) incubated with 100 ng/mL epidermal growth factor (EGF) for the depicted times, (B,C) preincubated with
1 µM erlotinib for 24 h before adding 100 ng/mL EGF for another 30 min, or (D) preincubated with 20 µM MK2206 for 24 h
before adding 100 ng/mL EGF for another 30 min. Proteins were separated on a 10% polyacrylamide gel and blotted on
a nitrocellulose membrane, and specific target proteins were detected using target specific primary and species-specific
secondary antibodies, coupled with horseradish peroxidase, as listed in the methods section. Signals were developed using
a chemoluminescence substrate and detected with the ChemoCam System (Intas, Göttingen, Germany). A representative
blot of at least three biological replicates is shown.
3.2. Bortezomib Reduces Cellular CIP2A Levels, Inhibits Akt Phosphorylation, and Induces p21
Expression and Cell Cycle Arrest in G2/M Phase
The proteasome inhibitor bortezomib has been shown to reduce cellular CIP2A protein
levels independently of its proteasome inhibition activity [14,15]. Bortezomib reduced
CIP2A protein levels at concentrations of 15 nM and 150 nM with accompanying reduc-
tion of PP2A inactivity marker pY307 and a reduction of pAkt in both HCC4006 and
HCC4006rErlo0.5 cell lines (Figure 3A, Supplementary Figure S2). Similarly, bortezomib
markedly induced p27 and strongly induced p21 in both cells lines (Figure 3B), which was
in line with a significant induction of cells arrested in the G2/M phase (33.3 ± 6.9% of
cells in G2/M with 15 nM bortezomib vs. 15.2 ± 1.9% at control conditions for HCC4006,
n = 7, p < 0.0001 and 34.5 ± 4.1% vs. 20.6 ± 1.1%, respectively for HCC4006rErlo0.5, n = 6,
p < 0.0001; one-way ANOVA with Dunnett’s Multiple Comparison Test; Figure 3C,D).
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Figure 3. Bortezomib downmodulates cell proliferation regulating inhibitor of phosphatase 2A (CIP2A), restores regulation
of Akt, and arrests cells in the G2/M phase of the cell cycle. Cells were incubated with 1 µM erlotinib, 15 nM bortezomib
(A,B) or 150 nM bortezomib (A) for 24 h. Proteins were separated on a 10% polyacrylamide gel and blotted on a nitrocellulose
membrane, and specific target proteins were detected using target specific primary and species-specific secondary antibodies,
coupled with horseradish peroxidase, as listed in the methods section. Signals were developed using a chemoluminescence
substrate and detected with the ChemoCam System (Intas, Göttingen, Germany). A representative blot of at least three
biological replicates is shown. (C) Distribution of the cell cycle phases was analyzed by propidium iodide staining of fixed
cells and detection of the fluorescence intensities using a MACSQuant flow cytometer after incubating the cells with 1 µM
erlotinib or 15 nM bortezomib for 24 h. (D) The relative amount of cells in each phase of the cell cycle is displayed as mean
± SD, n = 6, * p < 0.05, *** p < 0.001.
3.3. Combination Analyses Reveal Antagonistic Effects of Erlotinib and Bortezomib in HCC4006
Cells and Sensitization to Bortezomib in HCC4006rErlo0.5 Cells
First, combination effects were analyzed calculating the combination index, according
to the method of Chou-Talalay. This method is based on the concentration additivity
concept developed by Loewe et al. and proposes additive effects of substances given
similar targets and mode of actions [10].
Any deviation from additivity suggests interacting effects of the two substances. Cal-
culation of the combination indices revealed nonstatistical trends of synergistic effects at an
equimolar combination with 25 nM and antagonistic effects with 250 nM and 1000 nM of
both drugs for HCC4006 cells (Figure 4A). As calculation of the combination index requires
distinct IC50 values, this measure could not be calculated reliably for HCC4006rErlo0.5
cells. Therefore, a GPDI Model [12] was used for quantitative description of the interac-
tions (Figure 4B). In the sensitive HCC4006 cells, a full GPDI model on maximum effect
performed best. An antagonistic interaction was quantified in both directions (of very
similar magnitude), leading to deviations from BI when both erlotinib and bortezomib con-
centrations were >100 nM. In the resistant HCC4006rErlo0.5 cells, no interaction parameters
could be estimated precisely, indicating the lack of interaction. Indeed, a model assuming
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no significant interaction described the experimental data better than other GPDI model
candidates. In addition, the effect of bortezomib in HCC4006rErlo0.5 cells was increased,
compared to the sensitive HCC4006 cells (Emax of 0.911 instead of 0.585, a 55.7% increase
and EC50 of 52.4 nM, instead of 73.0 nM, a 28% decrease, Table 1).
Figure 4. Combination effects of erlotinib and bortezomib in HCC4006rErlo0.5 cells do not deviate from additivity.
(A) Viability of HCC4006 cells was assessed for combinations of equimolar concentrations of erlotinib (E) and bortezomib (B)
and combination index was calculated as explained in the methods section; values represent mean ± SD, n = 3. (B) Viability
of HCC4006 and HCC4006rErlo0.5 cells was assessed in a checkerboard format. Values represent means of three independent
experiments. Simulation was conducted as described in the methods section, * p < 0.05.
Table 1. Final General PharmacoDynamic Interaction (GPDI) model parameter estimates and their 95% confidence
intervals (CI) for the interaction between erlotinib and bortezomib in the non-small cell lung cancer cell line HCC4006 and
HCC4006rErlo0.5 which has been adapted to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib.
AIC: Akaike Information Criterion, EC50: Drug potency, the concentration at which half of the maximum effect is reached,
Emax: Maximum effect, H: Hill coefficient, sigmoidity of the concentration–effect relationship, GPDIINT: GPDI interaction
parameter, maximal effect of perpetrator on victim, EC50,INT: Potency of the interaction, concentration of the perpetrator at
which half of the maximum effect on the victim is reached, NA: not applied.
Parameters HCC4006 HCC4006rErlo0.5
AIC −565 −408
Erlotinib EC50 [nM] (95% CI) 35.2 (29.5–40.9) 3770 (−980–8514)
Emax (95% CI) 0.586 (0.573–0.600) 0.426 (0.306–0.546)
H (95% CI) 3.15 (1.90–4.41) 0.272 (0.157–0.387)
Bortezomib EC50 [nM] (95% CI) 73.0 (60.4–111) 52.4 (46.1–58.8)
Emax (95% CI) 0.585 (0.568–0.622) 0.911 (0.867–0.954)
H (95% CI) 20.7 (−35.2–115) 1.47 (1.19–1.75)
Erlotinib effect on bortezomib Emax
GDPIINT (95% CI) −0.492 (−0.595–−0.389) 0
EC50,INT [nM] (95% CI) 69.6 (38.6–101) NA
Bortezomib effect on erlotinib Emax
GDPI_INT (95% CI) −0.546 (−0.713–−0.380) 0
EC50,INT [nM] (95% CI) 117 (64.5–170) NA
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In order to confirm the hypersensitivity of HCC4006rErlo0.5 cells to bortezomib ob-
served in the model, we conducted live cell imaging of HCC4006 and HCC4006rErlo0.5
cells in the presence of 10 nM bortezomib over a time period of 72 h. In the presence
of 10 nM bortezomib HCC4006rErlo0.5 cells, cell death is induced as soon as 30 hours
after starting the bortezomib incubation. In contrast, in HCC4006 cells, the onset of cell
death induction was delayed to approximately 40 hours, with a subsequent delay in cell
death kinetics (Figure 5A, Supplementary Video). In order to quantify these effects, the
impact of bortezomib on clonogenic growth was assessed. The colonies surviving frac-
tion after an exposure to 10 nM bortezomib for two weeks were significantly reduced in
HCC4006rErlo0.5 cells, compared to HCC4006 cells (0.38 ± 0.18 vs. 0.95 ± 0.25, respectively,
p < 0.05, Figure 5B).
Figure 5. HCC4006rErlo0.5 cells are more sensitive to bortezomib compared to their native HCC4006 cells. (A) HCC4006 and
HCC4006rErlo0.5 cells were cultivated in a time-lapse microscope (Biostation II, Nikon Instruments, Düsseldorf, Germany)
at 37 ◦C and 5% CO2 atmosphere in the presence of 10 nM bortezomib. Representative images were taken at the indicated
time points. (B) Cells were plated in 150 mm cell culture dishes, and colonies were allowed to grow for 14 days. After
staining with crystal violet, colonies consisting of >50 cells were counted manually. The colonies surviving fraction was
calculated as described in the methods section. Values represent mean ± SD, n = 3, * p < 0.05.
4. Discussion
Exploring mechanisms of drug resistance to targeted small molecule drugs is critical
for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC)
patients carrying activating EGFR mutations. Sequential targeted therapy is currently
based on identifying secondary resistance mutations. However, in a substantial number of
patients, no secondary mutation can be found. Moreover, nongenetic mechanisms cannot be
detected. Here, we identified constitutive cell proliferation regulating inhibitor of protein
phosphatase 2A (CIP2A) in the HCC4006rErlo0.5 NSCLC cell line adapted to erlotinib
as a model of acquired drug resistance. Constitutive CIP2A resulted in a constitutive
activation of Akt signaling. The proteasome inhibitor bortezomib was able to reduce
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CIP2A levels which resulted in an activation of protein phosphatase 2A and deactivation of
Akt. Furthermore, accumulation of the cell cycle inhibitors p21 and p27 was accompanied
by a cell cycle arrest in the G2/M phase. Combination experiments with erlotinib and
bortezomib revealed a lack of interaction between the two drugs. However, the effect size
of bortezomib was higher in the adapted HCC4006rErlo0.5 resistance cell model, compared
to the erlotinib-sensitive HCC4006 cells, as indicated by an almost two-fold increase in Emax
and almost one-third decrease in EC50 in the concentration–effect model; an earlier onset
of cell death induction in live cell imaging experiments; and a reduced colony surviving
fraction in a colony formation assay.
CIP2A has been identified as a prognostic marker in non-small cell lung cancer, as its
expression was higher in lung tumor tissue compared to corresponding normal tissue [19],
and high levels of the protein in tumor samples were associated with reduced overall
survival [19–21]. In vitro, the role of CIP2A has mostly been investigated in cell model
systems that carry the wildtype EGFR. Knockdown of CIP2A resulted in a reduction of cell
proliferation and clonogenic growth, an increased induction of apoptosis, and an increased
sensitivity to cisplatin [22]. Furthermore, downmodulation of CIP2A has been shown to be
a prerequisite for sensitivity of EGFR wildtype NSCLC cell lines to EGFR tyrosine kinase in-
hibitors erlotinib [18,23] or afatinib [24] but also to natural compounds amentoflavone [25]
and polyphyllins [26,27]. In EGFR mutated cells that carry the secondary T790M mutation
and are intrinsically resistant to gefinitib, CIP2A downmodulation was shown to play
a critical role in the antitumor mode of action of the natural compounds oridonin [28]
and cucurbitacin B [29]. However, the role of CIP2A in the acquired resistance to EGFR
tyrosine kinase inhibitors in model systems carrying activating EGFR mutations has not
been investigated so far.
Aside from changes in CIP2A protein stability in HCC4006rErlo0.5 cells upon treatment
with erlotinib, we observed changes that were independent of erlotinib treatment in
HCC4006rErlo0.5 cells, compared to the parental HCC4006 cells. These were reduced levels
of p53 protein and a reduced basal- and ligand-induced EGFR activation. HCC4006 cells
carry the p53 Y205H mutation, which is associated with a median 15% transcriptional
activity, compared to wildtype p53 [30]. Downregulation of p53 has already been observed
in the course of acquired resistance to EGFR targeting drugs in lung cancer cell lines, and
reconstitution of p53 resulted in a resensitization of these cells to the drugs the cells were
adapted to [31,32]. However, these were cell lines carrying both wildtype p53 and EGFR.
As the HCC4006 carry both mutated p53 and EGFR, it is unlikely that reduced levels of
transcriptionally rather inactive p53 plays a major role for the resistance phenotype in our
HCC4006rErlo0.5 cell line. Constitutive activation of the EGFR in HCC4006 is an expression
of their oncogene addiction phenotype [33]. This is lost in the adapted HCC4006rErlo0.5
cells, which can be a result of several mechanisms, such as changes in cell surface receptor
density, receptor trafficking, or a reduction in ligand release and autocrine signaling.
The decrease in EGFR activity and the increase in responsiveness of HCC4006rErlo0.5
cells to bortezomib, together without deviation from additivity in the combination treat-
ment, suggests a switch in oncogene addiction from the EGFR to the Akt signaling pathway
regulated by the constitutive presence of CIP2A (Figure 6, bottom left). By downmodu-
lation of CIP2A, protein phosphatase 2A was reactivated to dephosphorylate Akt and to
restore cell growth inhibition programs (Figure 6, bottom right). In contrast, HCC4006
cells sensitive to erlotinib growth inhibition responded to erlotinib by downmodulation of
CIP2A (Figure 6, top right).
This is somewhat unexpected, as downmodulation of CIP2A has been described
in a rather treatment-unresponsive context so far. Interestingly, it was hypothesized
recently that effective oncogenic kinase inhibition requires the simultaneous activation of
the respective tumor suppressing phosphatase [34]. Our findings, thus, are well in line
with this hypothesis. Further extensive time-resolved investigations are needed to dissect
the interplay between EGFR receptor activation, signaling pathway activation, and signal
regression, together with the translational or posttranslational modulation of CIP2A.
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Figure 6. Schematic of the proposed mechanism of drug resistance of HCC4006rErlo0.5 cells developed against erlotinib.
Bortezomib is well-known as an inhibitor of the proteasome. In addition, there is
evidence that CIP2A undergoes proteasomal degradation [35,36]. However, is has been
shown in different model systems that the modulation of CIP2A induced by bortezomib
is independent of its proteasome inhibition activity but rather depends on inhibition of
transcriptional activity [37,38].
Sufficient activity of protein phosphatase 2A has been suggested as a general deter-
minant of cancer drug response [34]. However, the mechanisms that lead to an impaired
activity and, thus, cancer drug resistance, might vary substantially. Aside from CIP2A,
other oncogenic PP2A inhibitor proteins have been identified, which all inhibit PP2A by
different mechanisms [34]. In our cell system, we found CIP2A constitutively present in the
adapted HCC4006rErlo0.5 cells, escaping the downmodulating effect of erlotinib. Notwith-
standing, the underlying mechanism is unknown and currently under investigation in
our lab. We acknowledge that the findings reported here result from the investigation
of a single cell line pair. An analysis of cell lines of the Genomics of Drug Sensitivity in
Cancer database [39], however, revealed a significant correlation of CIP2A expression levels
and the gefitinib and erlotinib sensitivity, which was significant for gefitinib when the
analysis was restricted to lung cancer cell lines (Supplementary Figure S3). For erlotinib,
the correlation was not significant in the lung cancer cell lines, which is likely due to the
low number of lung cancer cell lines tested for erlotinib sensitivity. Taken together, these
data further support a role of CIP2A in the response of lung cancer cells to EGFR tyrosine
kinase inhibitors.
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A recent study using several sublines of a neuroblastoma cell line adapted to a small
molecule revealed a broad range of resistance phenotypes, despite their initial limited
intrinsic heterogeneity [40]. In non-small cell lung cancers (NSCLC) harboring EGFR muta-
tions, the understanding of molecular and genetic intratumor heterogeneity has emerged
as a pivotal task in the individualization process of cancer treatment [41]. Therefore, inves-
tigating the mechanisms of CIP2A stabilization in a range of NSCLC cell lines adapted to
EGFR tyrosine kinase inhibitors is needed to contribute to a better understanding of clonal
heterogeneity.
5. Conclusions
We have identified constitutive CIP2A in an EGFR-activating mutated cell model
system of acquired resistance to the EGFR targeting the small molecule inhibitor erlotinib.
Constitutive CIP2A could be downmodulated by the proteasome inhibitor bortezomib.
The erlotinib-resistant cells were more sensitive towards bortezomib, compared to their
erlotinib-sensitive parent cells. This suggests a switch in oncogene addiction and might
provide a potential strategy to overcome erlotinib resistance in NSCLC.
Supplementary Materials: The following are available online at https://www.mdpi.com/2073-440
9/10/4/716/s1, Figure S1: Downmodulation of CIP2A by erlotinib is abrogated in HCC4006rErlo0.5
cells; Figure S2: Bortezomib downmodulates CIP2A in HCC4006 and HCC4006rErlo0.5 cells and
restores regulation of Akt signaling; Figure S3: Correlation of CIP2A expression levels and the gefitinb
and erlotinib AUCs (areas under the curve) in the cell lines of the Genomcs of Drug Sensitivity in
Cancer database; Table S1: Shared Data; Video S1A: Live cell time-lapse of HCC4006 incubated with
10 nM bortezomib for 72 h; Video S1B: Live cell time-lapse of HCC4006rErlo0.5 incubated with 10 nM
bortezomib for 72 h.
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